The Pharmaceutical Industry’s Talent Paradox

GSK India’s ascension to the number one spot on TIME and Statista’s 2026 list of Best Employers highlights the complexities of attracting and retaining talent in the pharmaceutical sector. As a leading manufacturer of prescription medicines, vaccines, and consumer healthcare products, GSK India has achieved significant profits in recent years due to sustained demand for its products.

The company’s success can be attributed to growth projections that are expected to continue, with Deloitte India forecasting that the country’s pharmaceutical sector will reach $130 billion by 2030. India is emerging as one of the largest exporters of pharmaceuticals worldwide, shipping to over 190 countries.

However, beneath this impressive façade lies a talent acquisition conundrum. Despite its best efforts to attract and retain top talent, GSK India struggles to create an inclusive work environment that fosters innovation and creativity. Initiatives such as the xCEL Trainee Program for graduates and the GSK Scholars Programme aim to support students pursuing STEM education, but these programs are mere stopgap measures.

The reality is that India’s pharmaceutical industry faces a shortage of skilled workers due to an aging population and rapidly growing economy. With unprecedented demand for healthcare services and pharmaceutical products, many Indian students continue to shun careers in science, technology, engineering, and mathematics (STEM) due to reasons such as lack of job security, limited career progression opportunities, and the perception that these fields are overly competitive.

GSK India’s reliance on early career programs and scholarships underscores the industry’s failure to create a more inclusive work environment. Instead of merely offering entry-level positions or supporting students through educational initiatives, companies like GSK must rethink their approach to talent acquisition and retention. This includes providing attractive salaries, benefits packages, and opportunities for growth and development that reflect the value they place on their employees.

Moreover, India’s pharmaceutical industry must address its notorious reputation for exploiting workers. Despite being one of the country’s top industries attracting foreign investment, pharma has a history of labor disputes, worker exploitation, and inadequate working conditions. Companies like GSK India must prioritize employee welfare and safety above profits, recognizing that happy, motivated employees are essential to driving innovation and growth.

As Indian pharmaceutical companies move forward, they will need to reevaluate their approach to talent acquisition and retention. Rather than relying on short-term solutions or poaching talent from competitors, they should focus on creating a work environment that values diversity, inclusion, and employee well-being. Only then can the industry unlock its true potential and continue to grow.

The question now is whether GSK India’s peers will follow suit and adopt more inclusive policies. Can other top pharmaceutical companies learn from GSK’s success without sacrificing their own values and priorities? One thing is certain: only by putting people first can the Indian pharmaceutical industry truly thrive in an increasingly competitive global market.